N-(5-fluoro-2-phenoxyphenyl)-N-(2-hydroxy-5-methoxybenzyl)acetamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(5-fluoro-2-phenoxyphenyl)-N-(2-hydroxy-5-methoxybenzyl)acetamide
• 英文别名: DAA1123；N-(5-fluoro-2-phenoxy-phenyl)-N-(2-hydroxy-5-methoxy-benzyl)-acetamide；N-(2-hydroxy-5-methoxybenzyl)-N-(5-fluoro-2-phenoxyphenyl)acetamide；N-(5-fluoro-2-phenoxyphenyl)-N-[(2-hydroxy-5-methoxyphenyl)methyl]acetamide
• 化学式: C₂₂H₂₀FNO₄
• 分子量: 381.404
• InChiKey: BQGMMFZDQBVDCE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  59
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-(5-fluoro-2-phenoxyphenyl)-N-(2-hydroxy-5-methoxybenzyl)acetamide 以81的产率得到[11C]-DAA 1106
  参考文献：
  名称：

  Bioorganic & Medicinal Chemistry Letters 2003, 13, 201-204

  摘要：

  DOI：
• 作为试剂：
  描述：

  N-(5-fluoro-2-phenoxyphenyl)-N-(2-hydroxy-5-methoxybenzyl)acetamide 、 1-bromo-2-[¹⁸F]fluoroethane 在 N-(5-fluoro-2-phenoxyphenyl)-N-(2-hydroxy-5-methoxybenzyl)acetamide 作用下， 以29的产率得到¹⁸F-FEDAA1106
  参考文献：
  名称：

  Bioorg. Med. Chem. Lett. 2003, 13, 201-204

  摘要：

  DOI：

文献信息

• Use of radiolabelled phenyloxyaniline derivatives for imaging diseases associated with peripheral benzodiazepin receptor's activation
  申请人：Bayer Schering Pharma Aktiengesellschaft

  公开号：EP1997515A1

  公开（公告）日：2008-12-03

  The present invention relates to the use of a specific compound, as described in detail below, having a high affinity to the peripheral benzodiazepine receptor for imaging cardiac and cardiovascular diseases for which inflammation and/or mitochondrial dysfunction and any other pathophysiological process leading to PBR activation are major contributing factor.

  本发明涉及使用一种特定化合物，具有高亲和力与外周苯二氮卓啉受体结合，用于成像心脏和心血管疾病，其中炎症和/或线粒体功能障碍以及其他导致PBR激活的病理生理过程是主要的贡献因素。
• Phenyloxyaniline derivatives
  申请人：Bayer Schering Pharma Aktiengesellschaft

  公开号：EP1894915A1

  公开（公告）日：2008-03-05

  The present invention relates to phenyloxyaniline derivatives, to methods of their production and to uses thereof.

  本发明涉及苯氧基苯胺衍生物、其生产方法及其用途。
• AGENTS FOR THERAPY EFFICACY MONITORING AND DEEP TISSUE IMAGING
  申请人：Bornhop J. Darryl

  公开号：US20080031823A1

  公开（公告）日：2008-02-07

  Compounds and methods related to NIR molecular imaging, in-vitro and in-vivo functional imaging, therapy/efficacy monitoring, and cancer and metastatic activity imaging. Compounds and methods demonstrated pertain to the field of peripheral benzodiazepine receptor imaging, metabolic imaging, cellular respiration imaging, cellular proliferation imaging as targeted agents that incorporate signaling agents.

  与近红外分子成像、体外和体内功能成像、治疗/疗效监测以及癌症和转移活动成像相关的化合物和方法。展示的化合物和方法涉及外周苯二氮平受体成像、代谢成像、细胞呼吸成像、细胞增殖成像作为包含信号剂的靶向剂。
• PHENYLOXYANILINE DERIVATIVES
  申请人：LEHMANN Lutz

  公开号：US20110097269A1

  公开（公告）日：2011-04-28

  The present invention relates to phenyloxyaniline derivatives, to methods of their production and to uses thereof.

  本发明涉及苯氧基苯胺衍生物，其生产方法和用途。
• ARYLOXYANILIDE IMAGING AGENTS
  申请人：GE HEALTHCARE LIMITED

  公开号：US20140288317A1

  公开（公告）日：2014-09-25

  The present invention provides a novel radiolabelled aryloxyalinine derivative suitable for in vivo imaging. In comparison to known aryloxyalinine derivative in vivo imaging agents, the in vivo imaging agent of the present invention has better properties for in vivo imaging. The in vivo imaging agent of the present invention demonstrates good selective binding to the peripheral benzodiazepine receptor (PBR), in combination with good brain uptake and in vivo kinetics following administration to a subject.

  本发明提供了一种新型放射性标记的芳氧基丙氨酸衍生物，适合用于体内成像。与已知的芳氧基丙氨酸衍生物体内成像剂相比，本发明的体内成像剂具有更好的体内成像性能。本发明的体内成像剂在给予受试者后表现出良好的选择性结合外周苯二氮平受体（PBR），以及良好的大脑摄取和体内动力学。